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An overall and dose-response
meta-analysis of red blood cell
distribution width and CVD
outcomes
Haifeng Hou1,2,*, Tao Sun1,*, Cheng Li3,*, Yuanmin Li4, Zheng Guo1, Wei Wang1,2 & Dong Li1
Red blood cell distribution width (RDW) is the coefficient of variation of red blood cell size, considered
to be associated with cardiovascular disease (CVD). This study aimed to comprehensively synthesize
previous studies on RDW and CVD outcomes through an overall and dose-response meta-analysis.
PubMed, Embase and Web of Science were searched systematically for English and Chinese language
publications up to November 30, 2015. We extracted data from publications matching our inclusion
criteria for calculating pooled hazard ratio (HR), which was used to assess prognostic impact of RDW
on CVD. Twenty-seven articles, consisting of 28 studies and 102,689 participants (mean age 63.9 years,
63,703 males/36,846 females, 2,140 gender-unmentioned subjects) were included in the present
meta-analysis. The pooled HRs are 1.12 (95% CI = 1.09–1.15) for the association of all-cause mortality
(ACM) per 1% increase of RDW, 1.12(95% CI = 1.08–1.17) for major adverse cardiac events (MACEs) per
1% increase of RDW. A dose-response curve relating RDW increase to its effect on CVD outcomes was
established (pcurve < 0.001). For every 1-unit increase of RDW, there is an increased risk of occurrence of
ACM (pooled HR = 1.03, 95% CI = 1.02–1.04) and MACEs (pooled HR = 1.04, 95% CI = 1.01–1.06). This
study indicates RDW may be a prognostic indicator for CVD outcomes.
Red blood cell distribution width (RDW) is a quantitative parameter in routine hematologic analysis for representing the variation of red blood cell size. RDW is numerically expressed as the coefficient of variation for red
blood cell size (equal to standard deviation divided by mean) and has been used to differentiate the causes of
anemia for a long time1,2. Recently, the clinical significance of higher RDW has been considered in relation to
cardiovascular disease (CVD), autoimmune disease and respiratory disease3–6. In these non-hematologic disorders, RDW is one of significant indicators of morbidity and mortality7,8. Clinical studies conducted among
CVD patients have reported that RDW is a novel, independent predictor for all-cause mortality (ACM), and
major adverse cardiac events (MACEs) as well5,9–13, which is the most important outcomes of CVD. In particular,
MACEs include cardiovascular death, nonfatal myocardial infarction (MI) and heart failure (HF). Whereas the
results are inconsistent and the underlying mechanism is unclear14,15. Even though some meta-analyses have
combined the findings of RDW on predicting cardiovascular risk14,15, no dose-response meta-analysis has been
performed16. Thus, we conducted the first overall and dose-response meta-analysis to offer new evidence on the
association of RDW with CVD outcomes. The prognostic value of RDW for ACM and MACEs were then comprehensively reviewed among CVD (e.g. coronary artery disease, HF, MI) patients.

Results

Search results and study characteristics. As shown in flowchart (Fig. 1), our literature search returned
1,498 publications. After screening the title and abstract of these articles, we kept 126 ones for full-text review.
Consequently, this meta-analysis included 27 articles with 28 independent studies and 102,689 participants
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Figure 1. Flow chart of the study selection.

(mean age 63.9 years, 63,703 male/36,846 female, 2,140 gender-unmentioned subjects), the characteristics of
which were provided in Table 1.

Overall meta-analyses of prognostic value of RDW for ACM among CVD patients. As shown in
Fig. 2 and Supplementary Table 3, 19 original studies1,6,9,11,17–31 reported the prognostic risk of per 1% increase of
baseline RDW for all-cause mortality in CVD patients. After combining adjusted hazard ratios (HRs) and 95%
confidence interval (CI) of the 19 studies, we found that the ACM risk of CVD patients significantly increased by
12% (pooled HR = 1.12, 95% CI =  1.09–1.15, p = 0.000) per 1% increase of RDW among CVD patients. The heterogeneity test showed that statistical significance existed across all the studies (I2 =  69.3%, Q =  58.55, p =  0.000).
The subgroup analysis was conducted based on specific disease category. The pooled HRs (and 95% CIs) of ACM
were 1.11(1.07–1.14), 1.11(1.00–1.21), 1.21(1.11–1.32) among HF, MI and CAD patients, respectively. In addition, the results of subgroup analyses stratified by subject ethnicity, study design and follow-up duration were
presented in Supplementary Table 3.
Overall meta-analyses of prognostic value of RDW for MACEs among CVD patients. Eleven
studies5,17,20,22,26,28,29,31–34 addressed the relationship between per 1% increase of RDW and MACEs. The pooled
HR (1.12, 95% CI =  1.08–1.17, p = 0.000) indicated that increased RDW also facilitated MACEs among CVD
populations (Fig. 3). The heterogeneity was significant across the 11 studies (I2 =  63.4%, Q =  30.09, p =  0.003).
Then, we performed subgroup analyses based on disease classification, subject ethnicity, study design and
follow-up duration. As shown in Supplementary Table 4, the pooled HRs (95% CIs) were 1.11(1.05–1.17) among
HF patients, 1.14(1.08–1.21) among MI patients, and 1.12(1.08–1.17) among CAD patients, respectively.
Dose-response meta-analysis on relationship between RDW and ACM among CVD
patients. Twelve original studies within 11 articles2,8,20,23,27,28,35–39 were included in the dose-response

meta-analysis on prognostic value of RDW for all-cause mortality, in which the HRs of RDW classification (e.g.
tertile, quartile or quintile) for CVD risk were published. As the curve showed (Fig. 4A), the dose-response
relationship between RDW and ACM was significant (χ2 =  48.57, p = 0.000). The pooled HR was 1.03(95%
CI = 1.02–1.04) for every 1-unit increase of RDW among CVD patients.

Dose-response meta-analysis on relationship between RDW and MACEs among CVD
patients. Five studies2,12,20,28,40 were combined in the dose-response meta-analysis of association between

RDW level and MACEs. All studies provided the risks of RDW classification for MACEs. As shown in Fig. 4B,
a significant curve of dose-response relationship existed (χ2 =  10.25, p = 0.001), with the pooled HR being 1.04
(95% CI = 1.01–1.06) for every 1-unit increase of RDW.

Dose-response meta-analysis on relationship between RDW/Hb and outcomes of CVD. In
seven studies12,20,23,28,36,37,41 that reported mean hemoglobin(Hb) of subjects, the differences of Hb level between
all RDW classifications were significant. To adjust the confounding of anemia status for CVD patients, we normalized RDW with Hb through calculating the ratio of RDW to Hb. Furthermore, we performed a dose-response
meta-analysis to evaluate the prognostic value of RDW/Hb for ACM. As shown in Fig. 5A the curve of
dose-response relationship between RDW and ACM was obvious (χ2 =  34.87, p = 0.000). The pooled HR was
2.03(95% CI = 1.60–2.57) for every 1-unit increase of the RDW/Hb ratio. For the relationship between RDW/Hb
and MACEs, a significant curve of dose-response relationship exists (χ2 =  7.91, p = 0.048), with the pooled HR
being 1.58(95% CI = 1.09–2.29) for every 1-unit increase of RDW/Hb (Fig. 5B).
Sensitivity analysis. Anemia, resulting from percutaneous coronary intervention (PCI) in clinical settings,
may be a confounder in this study. Therefore we conducted a sensitivity analysis by excluding the original studies of Poludasu et al.38 and Uyarel et al.12, as these CVD patients were recruited undergoing PCI. The results
Scientific Reports | 7:43420 | DOI: 10.1038/srep43420
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Author

Year

Country

Disease

outcome

Sample size

Baseline

Follow up
duration

Allen LA

2010

USA

HF

ACM/MACE

1012

Age: 64 ± 14, 58% male

1.0 ±  0.3 y

Al-Najjar Y

2009

UK

HF

ACM

1087

Age: 60 ± 78, 74.3% male

52 m

Hazard Ratio (95% CI)
HR (a) =  1.07 (1.01–1.13)*
HR (m) =  1.05 (1.01–1.10)*
HR (a) =  1.12 (1.05–1.16)*
RDW ≤ 12.6, HR (a) =  1
RDW = 12.7–13.2, HR (a) =  1.2 (0.8–1.8)

Anderson JL

2007

USA

CAD

ACM

29526

Age: 61.1 ± 14.7, 62% male

4.9 y

Arbel Y (a)

2014

Israel

MI

ACM

535

Age: 60.5 ± 13.0, 80.1% male

5y

Arbel Y (b)

2014

Israel

CAD

MACE

3222

Age: 65.6 ±   ± 12.0, 72.7% male

415 d

HR (m) =  1.12 (1.07–1.18)*

Azab B

2011

USA

MI

ACM

619

Age: 64.1 ± 10.8, 69.7% male

4y

HR (a) =  1.104 (1.004–1.213)*

RDW = 13.3–14.0, HR (a) =  1.3 (0.9–1.8)
RDW ≥ 14.1, HR (a) =  1.8 (1.2–2.5)
HR (a) =  1.17 (1.025–1.34)*

RDW ≤ 12.9, HR (a) =  1
Benedetto U

2013

Italy & UK

CAD

ACM

8340

Age: 66 ± 13, 85% male

4485 d

RDW = 12.9–13.4, HR (a) =  1.47 (1.09–3.78)
RDW = 13.4–14.0, HR (a) =  2.47 (1.31–4.23)
RDW > 14, HR (a) =  3.44 (2.5–4.7)
HR (a) =  1.15 (1.07–1.22)*
HR (m) =  1.13 (1.06–1.21)*
RDW<13.8, HR (a) =  1
RDW = 13.8–14.8, HR (a) =  1.31 (0.83–2.06)
RDW = 14.8–16, HR (a) =  2.05 (1.33–3.16)

Bonaque JC

2012

Spain

HF

ACM/MACE

698

Age: 71 (62–77), 63% male

2.5 y

RDW >  16 = 3, HR (a) =  1.47 (2.29–3.16)
RDW<13.8, HR (m) =  1
RDW =  13.8–14.8,
HR (m) =  1.32 (0.86–2.02)
RDW = 14.8–16, HR (m) =   =  1.55 (1.02–2.37)
RDW > 16, HR (m) =  2.72 (1.83–4.05)

Cauthen CA

2012

USA

HF

ACM

6052

Age: 65 ± 14, 64.6% male

4.4 ±  2.4 y

HR (a) =  1.09 (1.01–1.17)*
RDW ≤ 12.8, HR (a) =  1
RDW = 12.9–13.2, HR ( (a) =  1.1 (0.6–2.1)

Dabbah S

2010

Israel

MI

ACM

1709

Age: 61 ± 12, 78.2% male

27 m

RDW = 13.3–13.7, HR (a)1.8 (1–3.2)
RDW = 13.8–14.3, HR (a) =  2 (1.1–3.4)
RDW ≥ 14.4, HR (a) =  2.8 (1.6–4.7)

Ephrem G

2013

US

MI

MACE

543

Age: 65 ± 13, 56% male

3.8 y

HR (m) =  1.35 (1.02–1.79)*
RDW ≤ 13.3, HR (a) =  1
RDW = 13.3–14.0, HR (a) =  1.2 (1–1.7)
RDW = 14.0–14.7, HR (a) =  1.1 (0.9–1.6)
RDW = 14.7–15.8, HR (a) =  1.5 (1.1–2)

Felker GM (1)
CHARM Cohort

2007

USA

HF

ACM/MACE

2679

Age: 64.1 ± 11.5, 66.6% male

34 m

RDW > 15.8, HR (a) =  1.7 (1.3–2.3)
RDW<13.3 =  1
RDW = 13.3–14, HR (m) =  1.1 (0.8–1.5)
RDW = 14–14.7, HR (m) =  1.2 (1–1.6)
RDW = 14.7–15.8, HR (m) =  1.5 (1.2–2)
RDW > 15.8, HR (m) =  1.9 (1.5–2.4)
RDW ≤ 13.0, HR (a) =  1

Felker GM (2)
Duke Databank

RDW = 13.1–13.6, HR (a) =  1.6 (1.1–2.5)
2007

USA

HF

ACM

2140

NA

4y

RDW = 13.7–14.2, HR (a) =  1.2 (0.8–1.8)
RDW = 14.3–15.3, HR (a) =  1.5 (1–2.2)
RDW > 15.3, HR (a) =  2.2 (1.5–3.3)

Gijsberts

2015

Netherla
nd

MI

ACM/MACE

1760

Age: 66.2 ± 10.9, 72.7% male

42 m

HR (a) =  1.25 (1.04–1.49)*
HR (m) =  1.19 (1.08–1.32)*

Jackson CE

2009

UK

HF

ACM

707

Age: 73 (67–80), 52% male

421 d

HR (a) =  1.06 (1.01–1.11)*

Jung C

2011

Geramny

HF

MACE

354

Age: 49 (median), 75.7% male

2579 d

HR (m) =  1.527 (1.274–1.831)*

Lappe J (a)

2013

USA

HF

ACM/MACE

6616

Age: 71.4 ± 14.6, 37.7% male

1m

HR (a) =  1.111 (1.06–1.16)*
HR (m) =  1.047 (1.01–1.08)*

Continued
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Author

Year

Country

Disease

outcome

Sample size

Baseline

Follow up
duration

Hazard Ratio (95% CI)
RDW<12.5, HR (a) =  1
RDW = 12.5–12.8, HR (a) =  1.46 (1.05–1.86)

Lappe JM (b)

2011

USA

CAD

ACM

1489

Age: 65.5 ± 11.3, 74.4% male

8.4–15.2 y

RDW = 12.9–13.3, HR (a) =  1.64 (1.3–1.98)
RDW = 13.4–14.2, HR (a) =  1.71 (1.53–1.88)
RDW > 14.2, HR (a) =  3.02 (2.12–3.92)
HR (m) =  1.19 (1.03–1.37)*
RDW<12.6, HR (m) =  1

Lee JH

2013

Korea

MI

MACE

1596

Age: 64.5 ± 11.9, 67.0% male

12 m

RDW = 12.7–13.1, HR (m) =  4.24
(1.41–12.75)
RDW = 13.2–13.9, HR (m) =  4.36
(1.47–12.91)
RDW > 13.9, HR (m) =  6.18 (2.1–18.21)
HR (a) =  1.15 (1.08–1.21)*
RDW ≤ 14.3, HR (a) =  1

Makhoul BF

2013

Israel

HF

ACM

614

Age: 77 ± 10, 45.9% male

1y

RDW = 14.4–15.2, HR (a) =  0.9 (0.6–1.3)
RDW = 15.3–16.5, HR (a) =  1.2 (0.8–1.7)
RDW ≥ 16.6, HR (a) =  1.9 (1.3–2.6)

Oh J

2012

Korea

HF

MACE

261

Age: 62.6 ± 14.2, 54.8% male

1m

HR (m) =  1.14 (1.042–1.247)*

Osadnik T

2013

Poland

CAD

ACM

2550

Age: 64.4 ± 9.3, 70.5% male

2.5 y

HR (a) =  1.23 (1.13–1.35)*

Pascual-Figal
DA

2009

Spain

HF

ACM

628

Age: 71 (61–77), 68% male

38.1 m

HR (a) =  1.074 (1.021–1.127)*

Poludasu S

2009

USA

CAD

ACM

859

Age: 62.3 ± 10.3, 49.4% male

4y

RDW = 13.3–15.7, HR (a) =  0.91 (0.41–2)

RDW<13.3, HR (a) =  1
RDW ≥ 15.7, HR (a) =  3.48 (1.36–8.9)
HR (a) =  1.19 (1.06–1.33)
Rickard J

2012

USA

HF

ACM

217

Age: 64.1 ± 11.8, 73.3% male

4.4 ±  1.8 y

Sahin O

2014

Turkey

MI

ACM

335

Age: 63 ± 13, 66.0% male

18 m

RDW<13.6, HR (a) =  1
RDW = 13.6–16.1, HR (a) =  1.19 (1.06–1.33)
RDW ≥ 16.1, HR (a) =  2.49 (1.13–5.44)
HR (a) =  0.97 (0.83–1.12)*
HR (a) =  1.14 (1.05–1.24)*
HR (m) =  1.08 (1.00–1.17)*
RDW ≤ 12.6, HR (a) =  1
RDW = 12.6–13.1, HR (a) =  1.29 (0.92–1.82)

Tonelli M

2008

CARE
study

CAD

ACM/MACE

4111

Age: 57.9 ± 9.2, 86.4% male

59.7 m

RDW = 13.1–13.7, HR (a) =  1.35 (0.97–1.88)
RDW ≥ 13.7, HR (a) =  1.78 (1.28–2.47)
RDW = 10.9–12.6, HR (m) =  1
RDW = 12.6–13.1, HR (m) =  1.19 (0.9–1.59)
RDW = 13.1–13.7, HR (m) =  1.39 (1.05–1.83)
RDW = 13.8–23.2, HR (m) =  1.56 (1.17–2.08)

Tseliou E

2014

Greece

HF

ACM/MACE

80

Age: 57.8 ± 12.4, 97.6% male

6m

Uyarel H

2011

Turkey

MI

MACE

2506

Age: 56.6 ± 11.8, 82.8% male

21 m

van Kimmenade

2009

USA

HF

ACM

205

Age: 73.1 ± 13, 51.2% male

1y

Yao HM

2014

China

CAD

ACM/MACE

2169

Age: 60.2 ± 10.9, 67.7% male

2y

HR (a) =  1.15 (1.05–1.27)*
HR (m) =  1.15 (1.05–1.27)*
RDW<14.8, HR (m) =  1
RDW > 14.8, HR (m) =  1.831 (1.034–3.24)
HR (a) =  1.03 (1.02–1.07)*
HR (a) =  1.37 (1.15–1.62)*
HR (m) =  1.21 (1.04–1.39)*
RDW ≤ 13.2, HR (a) =  1

Yu SB

2012

China

HF

ACM

16681

Age: 66 (54–74), 49.3% male

3y

RDW = 13.3–14.1, HR (a) =  0.892
(0.818–0.973)
RDW = 14.2–14.8, HR (a) =  0.859
(0.793–0.931)
RDW ≥ 14.9, HR (a) =  1.034 (0.961–1.111)

Continued
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Author

Year

Country

Disease

outcome

Sample size

Baseline

Follow up
duration

Hazard Ratio (95% CI)
HR (a) =  1.20 (1.11–1.29)*
RDW ≤ 14, HR (a) =  1

Zalawadiya SK

2011

USA

HF

ACM

789

Age: 62.7 ± 15.1, 50% male

573 d

RDW = 14.01–15.20, HR (a) =  1.73
(0.94–3.19)
RDW = 15.21–16.50, HR (a) =  2.44
(1.34–4.47)
RDW > 16.5, HR (a) =  3.21 (1.77–5.83)

Table 1. Characteristics of included studies on association of RDW with outcomes of CAD. *Analysis for
risk of per 1% increase of RDW; HR (a): hazard ratio for ACM; HR (m): hazard ratio for MACE; ACM: all-cause
mortality; MACE: major adverse cardiac event; HF: heart failure; MI: myocardial infarction; CAD: coronary
artery disease; 95% CI: 95% confidence intervals; d: days; m: months; y: years.
indicated that curve relationship between every 1-unit increase of RDW and adverse outcomes of CVD was
significant, with a HR of 1.03(95% CI =  1.14–1.04, p = 0.000) for ACM and 1.04(95% CI =  1.01–1.06, p =  0.012)
for MACEs (Supplementary Figures 1–2). Further sensitivity analysis was performed to detect the stability of this
meta-analysis by removing each study sequentially. Consequently, no obvious change was generated for omission
of each study except van Kimmenade’s research6. The detailed results of sensitivity analysis were described in
Supplementary Figures 3–4.

Publication bias.

The funnel plot is used to explore potential publication bias of the current meta-analysis.
Supplementary Figures 5–6 demonstrates that publication bias was statistically significant.

Discussion

In this systematic review, we included 27 articles consisting of 28 original studies and 102,689 subjects. The
pooled results demonstrated that baseline RDW level was remarkably associated with CVD outcomes. We found
a 0.12-fold elevation for all-cause mortality risk in CVD patients per 1% increase of RDW. Increased RDW is also
an effective predictor for MACEs with a HR of 1.12. The novel approach of dose-response meta-analysis identified
the curve of dose-response relationship between RDW and CVD outcomes.
Red blood cell distribution width (RDW) is a parameter of the heterogeneity of circulating erythrocytes size,
which was reported to be associated with CVD1,2,6,12,28,37,38. Although the mechanism of this association is not
fully understood, RDW is considered to be an indicator of inflammation, and is implicated in several inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)19,42.
Inflammatory stress leads to dysfunctional bone marrow with ineffective production of red blood cells18, disturbs
the red cell membrane and effectively causes the migration of reticulocytes into the peripheral circulation. This
induces an increase in the proportion of immature RBCs in the circulation, resulting in higher RDW levels42.
Moreover, inflammation up-regulates the expressions of complement protein receptors (C1qRs) and toll-like
receptors (TLRs) in platelets. This contributes to platelet activation, accelerating the progression of inflammatory
diseases, such as CVD18. It is clear that the inflammatory process is a principal pathophysiologic pathway in the
development of CVD and CVD events43–46. In addition, an increase in RDW is related to increased oxidative
damage in blood circulation, which associates with exacerbation of CVD47.
Hemodynamic status, reported by Salvagno et al., may play a role in association of RDW with CVD48. RBCs
may become entrapped in atherosclerotic plaque by the occurrences of fibrous cap damage, thrombus formation or plaque hemorrhage resulting from injury of intraplaque microvessels. In these instances, RBCs accelerate atherogenesis locally in the damaged area. The high anisocytosis of RBCs, exhibited as increased RDW,
causes decreased erythrocyte deformability. This may increase blood viscosity, disturb blood flow through the
microcirculation, and promote the adverse consequences of a pre-existing vascular occlusion in CVD. Therefore,
increased RWD levels may contribute to the identification of CVD patients who require more intensive therapy18.
Many clinical studies and several meta-analyses have been conducted to explore the application measures of the easily acquired routine blood index, and to study the prognostic significance of RDW among
CAD or HF patients14,15. Whilst they have provided effective methods with valuable results, no authors conducted dose-response meta-analysis. Does–response meta-analysis is a new method of systematic review and
meta-analysis for assessing the effect of continuous quantitative variables on diseases16. Compared to previous
meta-analyses, our study found a dose-response relationship between RDW and CVD outcomes.
Although RDW is a recognized parameter associated with anemia, no study has provided an explicit baseline
for anemia with exception to hemoglobin (Hb) levels in subjects. In the present study, we calculated the pooled
HR, for which Hb and other confounding factors were adjusted with multiple statistical model. A recently publication verified that RDW was an independent risk factor related to mortality of post-PCI non-anemia patient49.
This finding indicates that RDW is an independent predictor of CVD mortality49. To further adjust the effect of
anemia on our results and explore the appropriate rheological role of related risk factors, we normalized RDW
with Hb. We found that the ratio of RDW/Hb is significant for predicting CVD outcomes in a dose-response
manner. This is the first report demonstrating the prognostic value of the normalized RDW (i.e. RDW/Hb) on
CVD outcomes. As RBC count is also considered to be independently associated with CVD risk50, we suggest
that other approaches of normalizing RDW, such as the ratio of RBC count, might be utilized in further relevant
studies for the purpose of explaining rheological role of RDW on CVD outcomes.
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Figure 2. Forest plot of the pooled adjusted HR of per 1% RDW increase for the risk of all-cause mortality
in overall meta-analysis. The size of each grey square is proportional to the study’s weight calculated in the
meta-analysis. HR: hazard ratio; 95% CI: 95% confidence interval; HF: heart failure; MI: myocardial infarction;
CAD: coronary artery disease.

Figure 3. Forest plot of the pooled adjusted HR of per 1% RDW increase for the risk of MACEs in overall
meta-analysis. The size of each grey square is proportional to the study’s weight calculated in the meta-analysis.
HR: hazard ratio; 95% CI: 95% confidence interval; HF: heart failure; MI: myocardial infarction; CAD: coronary
artery disease.

Moreover, the treatment of PCI plays a crucial role in post-PCI anemia because of arterial vessel wall injury
and further antiplatelet or antithrombotic medication during the PCI procedure. Post-PCI anemia is also
reported to increase the risk of CVD in patients51. Further, our sensitivity analysis, excluding the original studies
conducted among participants undergoing PCI, showed a significant dose-response relationship between RDW
and CVD outcomes.
The present study has certain limitations. Firstly, the heterogeneity across individual studies was not avoided
completely. Secondly, we did not conduct subgroup analyses based on gender and age stratifications because
no original articles reported the detailed HRs stratified by age and gender. Thirdly, the potential publication
bias might disturb the quality of meta-analysis. Publication bias is a disadvantage in systematic reviews and
meta-analyses, which needs to be mitigated as much as possible at the onset of original studies. When researchers evaluate the risks of RDW and other variables on CVD outcomes, the COX proportional hazards regression model would be utilized to calculate the adjusted HRs, which then presented the independent risk degrees.
However, the non-significant HRs were not included in the original publications. This is problematic for us to
further systematic reviews and meta-analyses referring to these studies, as only the significant adjusted HRs were
included in synthesized HRs. Undoubtedly, this induced a publication bias into our studies. In order to avoid
Scientific Reports | 7:43420 | DOI: 10.1038/srep43420
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Figure 4. Dose-response relationship between RDW (per 1-unit increase) and CVD outcomes. (A)
Relationship between RDW and all-cause mortality. (B) Relationship between RDW and MACEs. Dotted lines
represent the 95% CI for the fitted trend. LCI: lower limit of confidence interval; UCI upper limit of confidence
interval; 95% CI: 95% confidence interval; RDW: red blood cell distribution width.

this kind of bias in the future, the following methods should be implemented: (1) all results of statistical analysis
should be reported, (2) when employing a stepwise method for COX regression analysis, the variables in the multivariate model equation and those not in the equation should be involved simultaneously; otherwise, the enter
model should be applied to include each variable in multivariate statistical analysis.
In spite of the afore-mentioned limitations, this study presents new comprehensive evidence for the association between RDW and CVD outcomes. We might conclude that increased RDW is a prognostic indicator for
CVD outcomes with a dose-response manner.

Methods

This meta-analysis is conducted according to the published criteria of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA)14,15. The PRISMA Checklist form is listed in Supplementary Table 1.

Search strategy. We identified relevant studies on the association between RDW and adverse outcomes
among CVD patients (i.e. coronary artery disease, MI, and HF). The search approach was performed to retrieve
articles from PubMed, Embase and Web of Science databases published in English and Chinese up to November
30, 2015. The search strategy was designed with the following terms: “red cell distribution width” or “red blood
cell distribution width” or “RDW”, “mortality”, “CVD events”, “cardiovascular disease” or “CVD”, “coronary artery
disease” or “CAD”, “myocardial infarction” or “MI”, and “heart failure” or “HF”. Further manual collection of references attached on retrieved papers was performed to screen potential relevant studies.
Selection criteria.

We included studies that fulfilled the following inclusion criteria: (1) the baseline or
admission serum RDW level was reported; (2) prospective study or retrospective study that evaluated the prognostic value of RDW for CVD patients; (3) one of the following outcomes was reported: all-cause mortality
(ACM), fatal CVD events (cardiovascular death), non-fatal CVD events (e.g. MI, stroke, HF and readmission
for CVD); (4) studies performed in participants aged ≥18 years. We excluded studies that matched any of the
following exclusion criteria: (1) duplicated data; (2) researches based on animal or cell line design; (3) no full data
can be obtained.

Quality assessment and data extraction. Two authors independently reviewed relevant articles. The
quality of each study was assessed with the scale for quality assessment (Supplementary Table 2) generated
according to the PRISMA statement and the Meta-analysis of Observational Studies in Epidemiology (MOOSE)
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Figure 5. Dose-response relationship between RDW/Hb (per 1-unit increase) and adverse cardiovascular
event risk. (A) Relationship between RDW and all-cause mortality. (B) Relationship between RDW and
MACEs. Dotted lines represent the 95% CI for the fitted trend. LCI: lower limit of confidence interval; UCI
upper limit of confidence interval; 95% CI: 95% confidence interval; RDW: red blood cell distribution width;
Hb: hemoglobin.

guidelines15. The studies labeled high quality with score ≥6 were included in the current meta-analysis. The third
reviewer (D.L.) contributed to the resolution of inconsistent opinions.
The following data for eligible studies were extracted independently: year of publication, name of first author,
duration of follow-up, location of study population, number of participants, characteristics of patients or controls, definition of outcome, adjusted HR for per 1% increase of RDW for CVD risk, adjusted HR for each RDW
classification compared to reference level. We also checked the online Supplementary Data of published articles
when necessary.

Data synthesis and statistical analysis. The STATA 14.0 software (by Stata Corp, College Station, TX,
USA) was utilized to analyze data. We combined HR values to identify the prognostic risk of per 1% increase
of RDW for CVD based on the original studies reporting quantitative RDW levels. For other studies which
addressed ordinal classification of RDW levels, the dose-response meta-analysis was performed to synthesize
pooled HRs and the curve of dose-response relationship with the method of Greenland and Longnecker16. The
number of cases, person-years or numbers of all participants are required for this methodology, and the HR (and
95% CI) for at least three RDW categories are required as well. For the studies that did not publish the number
of cases or person-years in each RDW level, the data were calculated approximately from total number of cases,
person-years and HR in this study. The I2 and Q-test was performed to detect the heterogeneity across included
studies. The fixed effects model was used to combine the original data when the heterogeneity was not statistically
significant. Otherwise, the random effects model analysis was used when heterogeneity was considered to be significant (p was < 0.10 and I2 was >50%). Furthermore, subgroup analyses were performed to explore the sources
of heterogeneity according to study characteristics in terms of study design, type of disease, follow-up duration
and ethnicity of subject. Sensitivity analyses were conducted to evaluate the stability of results in the current
meta-analysis. Funnel plot analysis was implemented to detect potential publication bias52.
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